SciHub
文献互助
期刊查询
一搜即达
科研导航
交流社区
登录
注册
发布
文献
求助
首页
我的求助
捐赠本站
清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!
tutu
Lv1
40 积分
2023-10-08 加入
最近求助
最近应助
互助留言
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
6天前
已完结
Diagnosis and Treatment of Metastatic Colorectal Cancer
8天前
已完结
Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab
10天前
已完结
Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer
18天前
已完结
DNA Mutational Profiling in Patients With Colorectal Cancer Treated With Standard of Care Reveals Differences in Outcome and Racial Distribution of Mutations
21天前
已完结
Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer
25天前
已完结
Palbociclib inhibits the progression of head and neck cancer and improves the Cetuximab response under specific condition in vitro and in vivo
1个月前
已完结
First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion–Positive NSCLC
1个月前
已完结
Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions
1个月前
已完结
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
1个月前
已完结
没有进行任何应助
速度真快
8天前
点赞
18天前
感谢
21天前
点赞
25天前
点赞
1个月前
速度真快,点赞
1个月前
点赞
1个月前
点赞
1个月前
感谢
1个月前
感谢
4个月前
最近帖子
最近评论
没有发布任何帖子
没有发布任何评论